| 词条 | Galidesivir |
| 释义 |
| IUPAC_name = (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol | image = BCX4430.svg | tradename = | legal_US = Investigational new drug | bioavailability = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 222631-44-9 | PubChem = 69211190 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = OLF97F86A7 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ChemSpiderID = 8620968 | C=11 | H=15 | N=5 | O=3 | molecular_weight = 265.268 | smiles = O[C@H]3[C@H](c2c1ncnc(N)c1[nH]c2)N[C@H](CO)[C@H]3O | StdInChI = 1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1 | StdInChIKey = AMFDITJFBUXZQN-KUBHLMPHSA-N }}Galidesivir (BCX4430, Immucillin-A) is an antiviral drug, an adenosine analog[1] (a type of nucleoside analog).[2] It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, flaviviruses and phleboviruses.[3] BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection,[1] and development for use in humans is being fast-tracked due to concerns about the lack of treatment options for the 2013-2016 Ebola virus epidemic in West Africa.[4] BCX4430 also showed efficacy against Zika virus in a mouse model, though there are no plans for human trials at this stage.[5] See also
References1. ^1 {{cite journal | vauthors = Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S | display-authors = 6 | title = Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 | journal = Nature | volume = 508 | issue = 7496 | pages = 402–5 | date = April 2014 | pmid = 24590073 | doi = 10.1038/nature13027 | bibcode = 2014Natur.508..402W }} {{RNA antivirals}}{{Ebola}}{{pharm-stub}}2. ^{{cite journal | vauthors = Kamat SS, Burgos ES, Raushel FM | title = Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate | journal = Biochemistry | volume = 52 | issue = 42 | pages = 7366–8 | date = October 2013 | pmid = 24111876 | pmc = 3838859 | doi = 10.1021/bi4013287 }} 3. ^Westover JB, et al. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral Res. 2018 Aug;156:38-45. {{Cite journal|doi=10.1016/j.antiviral.2018.05.013|pmid=29864447|pmc=6035881|year=2018|last1=Westover|first1=J. B.|title=Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters|journal=Antiviral Research|volume=156|pages=38–45|last2=Mathis|first2=A.|last3=Taylor|first3=R.|last4=Wandersee|first4=L.|last5=Bailey|first5=K. W.|last6=Sefing|first6=E. J.|last7=Hickerson|first7=B. T.|last8=Jung|first8=K. H.|last9=Sheridan|first9=W. P.|last10=Gowen|first10=B. B.}} 4. ^{{cite web |url=https://www.forbes.com/sites/paulrodgers/2014/08/04/biowar-lab-develops-cure-for-ebola/ |title=BioWar Lab Helping To Develop Treatment For Ebola |first=Paul |last=Rodgers | name-list-format = vanc |work=Forbes Magazine |date=8 April 2014 }} 5. ^{{cite journal | vauthors = Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, Stewart J, Collins P, Gebre M, Neilson S, Van Wettere A, Lee YM, Sheridan WP, Morrey JD, Babu YS | display-authors = 6 | title = Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model | journal = Antiviral Research | volume = 137 | pages = 14–22 | date = January 2017 | pmid = 27838352 | pmc = 5215849 | doi = 10.1016/j.antiviral.2016.11.003 }} 6 : Anti-RNA virus drugs|Antivirals|Ebola|Nucleosides|Experimental drugs|Pyrrolopyrimidines |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。